Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal imaging changes with cardiac myosin inhibitor therapy in adult hypertrophic cardiomyopathy
ChiCTR2500112074Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Global longitudinal strain. Started Nov 2025; status: recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ChiCTR2500112074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112074.